FibroGen to Present at Cowen’s 43rd Annual Health Care Conference

Rhea-AI Summary

FibroGen (NASDAQ: FGEN) announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference held in Boston from March 5-8, 2023. The panel will focus on Respiratory/Infections and is scheduled for March 8, 2023, at 10:30 AM Eastern Time. Investors can access a live audio webcast on the FibroGen Investor webpage, with a replay available for approximately 30 days. FibroGen continues to innovate in biopharmaceuticals, focusing on therapies for conditions such as idiopathic pulmonary fibrosis and anemia associated with myelodysplastic syndromes.

SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen’s 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023. Details of the presentations are as follows:

Panel Information:
Date: Wednesday, March 8, 2023
Panel topic: Respiratory/Infections
Time: 10:30 AM Eastern Time

A live audio webcast of the event will be available to investors and other interested parties on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days.

About FibroGen  
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and Duchenne muscular dystrophy (DMD). Roxadustat (爱瑞卓^®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS), and in Phase 3 clinical development in China for treatment of chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com. 

Contacts:
FibroGen, Inc.
Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
415.978.1434
mtung@fibrogen.com

Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

FAQ

When will Mark Eisner participate in the Cowen Health Care Conference?

Mark Eisner, M.D., M.P.H. will participate on March 8, 2023, at 10:30 AM Eastern Time.

What topics will be discussed at the Cowen Health Care Conference?

The panel will cover topics related to Respiratory/Infections.

How can I watch the FibroGen panel discussion?

The event can be accessed via a live audio webcast on the FibroGen Investor webpage.

What is the focus of FibroGen's drug development?

FibroGen focuses on developing therapies for idiopathic pulmonary fibrosis, cancer, and anemia.

What is the stock symbol for FibroGen?

The stock symbol for FibroGen is FGEN.